The DOI matches its Crossref record; 110 of the 114 references it cites were found in a registry or an index.
The Dual Roles of NRF2 in Cancer
Open accessAbstract
NRF2 has been traditionally considered as a tumor suppressor because its cytoprotective functions are deemed to be the main cellular defense mechanism against exogenous and endogenous insults, including xenobiotics and oxidative stress. However, several recent studies demonstrate that hyperactivation of the NRF2 pathway creates an environment that favors the survival of normal as well as malignant cells, protecting them against oxidative stress, chemotherapeutic agents, and radiotherapy. In a rapidly advancing field, this review summarizes some of the known mechanisms by which NRF2 can exert its oncogenic functions, and describes the current status of NRF2 inhibitors, providing a clear rationale for the consideration of NRF2 as a powerful putative therapeutic target in cancer treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [8]
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [8]
In the citing paper
“In this regard, mutations to NRF2 and its regulator KEAP1 have been found in cancer cells, supporting the supposition that antioxidant genes are pivotal in tumor progression59–62.”
From ROS in cancer therapy: the bright side of the moon (2020) · cites this paper as [61]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., & Yamamoto, M. (1999) · Genes & Development · doi:10.1101/gad.13.1.76 · Cited by 3,634
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Komatsu, M., Kurokawa, H., Waguri, S., Taguchi, K., Kobayashi, A., Ichimura, Y., Sou, Y.-S., Ueno, I., Sakamoto, A., Tong, K. I., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2021 · Cited by 2,288
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Kobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224
Nrf2–Keap1 defines a physiologically important stress response mechanism
Motohashi, H., & Yamamoto, M. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.09.003 · Cited by 1,725 · cited 1×
“NRF2: Tumor Suppressor or Oncogene? The main function of the transcription factor NRF2 [also known as NFE2L2, nuclear factor (erythroid-derived-2)-like 2] is to activate the cellular antioxidant response by inducing the transcription of several genes to protect cells from the effects of exogenous and endogenous insult…”
BackgroundMoi, P., Chan, K., Asunis, I., Cao, A., & Kan, Y. W. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9926 · Cited by 1,607
Guichard, C., Amaddeo, G., Imbeaud, S., Ladeiro, Y., Pelletier, L., Benmaad, I., Caldéraro, J., Bioulac‐Sage, P., Letexier, M., Degos, F., et al. (2012) · Nature Genetics · doi:10.1038/ng.2256 · Cited by 1,522
Flagged first, then by citations
4 of the 114 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 601–637 of 637
Amiri‐Ardekani, E., Radfar, A., Tavakoli-far, F., Farkhondeh, T., Aschner, M., Samini, F., & Samarghandian, S. (2025) · Current Nutrition & Food Science · doi:10.2174/0115734013328720241112032005
Abalenikhina, Y. V., Николаевна, С. О., Kostyukova, E. V., Shchulkin, A. V., & Topunov, A. F. (2025) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683824608114
Taddei, I., Cirotti, C., Lamballe, F., Castellanet, O., Maina, F., Medici, V., Fierro, F., Corleone, G., Nicola, F. D., Fanciulli, M., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6855159/v1
RSL1D1 regulates lung adenocarcinoma progression by inhibiting NRF2 ubiquitination
Yang, Q., Zhang, C., Zhang, H., sun, S., Zhao, G., Yang, Q., Huang, X., Yan, E., Li, H., Liu, H., et al. (2025) · Gene · doi:10.1016/j.gene.2025.149637
Song, C., Choi, Y., Kim, N., Nam, R. H., Kim, J. W., Jang, J. Y., Kim, E. H., Ha, S., & Lee, H. (2025) · The World Journal of Men s Health · doi:10.5534/wjmh.250061 · Cited by 1
Genetic evidence for causal effects of inflammatory protein factors on breast cancer
Liu, X., Xu, X., Ye, P., Jiang, Z., Tian, L., Yin, Y., & Li, F. (2025) · Discover Oncology · doi:10.1007/s12672-025-03370-w
Omaveloxolone: a nuclear factor erythroid 2-related factor 2 activator for Friedreich’s ataxia
Zhao, Z., Wang, J., Lu, M., You, Q., & Jiang, Z. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00038-x
Gelerstein-Claro, S., Espinoza-Jaña, B., Chichiarelli, S., Saso, L., & Rodrigo, R. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001367
Lead induces cell-autonomous proliferation and metabolic reprogramming of hepatocytes
Serra, M., Smiriglia, A., Migliore, C., Caddeo, A. M., Lorito, N., Tani, G., Zedda, G., Columbano, A., Perra, A., Giordano, S., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08134-6
Self-citationRearrangement of signaling pathways and adaptation of tumor cells to hypoxia
Andreeva, O. E., Mikhaevich, E. I., & Ma, K. (2025) · Advances in molecular oncology · doi:10.17650/2313-805x-2025-12-4-8-23
Liu, Y., Li, K., Li, C., Feng, Z., Cai, Y., Zhang, Y., Hu, Y., Wei, X., Yao, P., Liu, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26665051
Manman, L., Wang, L., Sun, Z., Chen, X., Wang, H., Qin, L., Zhao, W., & Geng, B. (2022) · Figshare · doi:10.6084/m9.figshare.19738699
Zou, Y., Cao, Z., Wei, L., Tang, H., Ji, W., Xiao, N., & Zeng, Y. (2026) · Current Cancer Therapy Reviews · doi:10.2174/0115733947399339251106102000
He, C., Jiang, J., Hou, S., Xu, R., & Huang, Q. (2026) · Food and Chemical Toxicology · doi:10.1016/j.fct.2026.115986
Anti-cancer mechanism of traditional Chinese medicine natural products targeting ferroptosis
Zhou, J., Lu, P., Guo, M., Chen, X., Chai, K., Wang, H., Zhou, L., Zhai, Y., Li, J., Qiao, C., et al. (2026) · Chinese Medicine · doi:10.1186/s13020-026-01363-7
Lu, P., Shangguan, W., Qian, W., Wu, D., Li, W., Huang, J., Xu, P., Chen, D., Li, F., Chen, B., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08591-7
Drépanocytose et polymorphismes génétiques : épidémiologie, prédiction de gravité et stress-oxydant
Gueye, F. (2019) · theses.fr (ABES) · doi:10.70675/ba1cd2c2z7fe6z4d0dzb10fz91439ce84eb9
Protéostase cellulaire et tumeurs solides
Sauzay, C. (2018) · theses.fr (ABES) · doi:10.70675/34bdea7fz8e7bz4ba1z997ez5d01dd3c712e
Fu, W., Yan, Y., Tian, F., Shu, C.-H., Yang, F., Xia, Y., Chen, X., Chen, J., Jiang, Y., Cui, R., et al. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109956
Barbolov, M., Stoyanov, S., Радева, М., Boshnakov, P., Yaneva, G. A., Ivanova, D. G., & Tasinov, O. (2026) · Foods · doi:10.3390/foods15122106
Gęgotek, A., Jarocka-Karpowicz, I., Mucha, M., & Skrzydlewska, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125551
Recent advances in phytomedicine-based nano-antioxidants for redox-modulated cancer therapy
Faridi, U. A., Almutairi, F. M., Sakran, M., Zidan, N., Alalawy, A. I., Al-Awthan, Y., Akhtar, Q., & Atteia, H. (2026) · Cancer Nanotechnology · doi:10.1186/s12645-026-00401-1
Yang, T., Qiu, C., Li, Y., Zhang, Y., Wang, C., Zhou, J., Chu, Z., Ma, A., Huang, L., Wong, Y. K., et al. (2026) · Advanced Science · doi:10.1002/advs.202520252
Nano-Radiosensitizers for Radiotherapy: Design Strategies and Antitumor Immune Responses
Song, R., & Lin, W. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.6c00136
Roungeri, E., Konstantinou, E. K., Dimiza, K., Dimitriou, M., Darras, A. I., & Panagiotopoulos, A. A. (2026) · Scientia Pharmaceutica · doi:10.3390/scipharm94030077
L013 promotes NRF2 degradation in NRFA-subtype esophageal squamous cell carcinoma
Yu, X., Wu, Y., Sun, X., Han, R., Cai, Y., Zeng, W., Li, Y., Wang, Y., Zhao, Y., Rao, Y., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103046
Choi, H. Y., Kwon, H., & Hah, Y. (2026) · Antioxidants · doi:10.3390/antiox15101223
Gunawan, V. A., Sumarawati, T., Putra, A., Setiawan, E., Trisnadi, S., Chodijah, C., & Amalina, N. D. (2026) · Journal of Research in Pharmacy · doi:10.12991/jrespharm.1684891
Fumarate and Its Esters: Physiology, Pathology, Molecular Mechanisms, Diseases, and Therapy
Zhu, P., You, M., Zeng, Y., Zhang, J., Chen, S., Rong, R., & Xia, X. (2026) · MedComm · doi:10.1002/mco2.71059
Wang, F., Wu, J., Wang, W., Zhao, R., Mao, Y., Wu, F., Li, Y., Pingjiang, G., Zhu, W., Yan, X., et al. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1944888
BindingDB (2020) · UC San Diego · doi:10.7270/q2n0192h
BindingDB Entry 50019686: Stapled Peptides as Direct Inhibitors of Nrf2-sMAF Transcription Factors.
BindingDB (2024) · UC San Diego · doi:10.7270/q2qj7np4
Metadata
- Authors
- Menegon, S., Columbano, A., & Giordano, S.
- Affiliations
- Candiolo Cancer Institute (IT)
- University of Cagliari (IT)
- Corresponding author
- Menegon, Silvia
- Columbano, Amedeo
- Giordano, Silvia
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 22
- Issue
- 7
- Pages
- 578-593
- ISSN
- 1471-4914 (ISSN-L)
- OpenAlex
- W2417535489
- Cited by
- 633
- References
- 114
- Citations by year
- 2026: 28 · 2025: 43 · 2024: 64 · 2023: 60 · 2022: 74 · 2021: 75 · 2020: 69 · 2019: 72 · 2018: 73 · 2017: 57 · 2016: 16
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Trends in Molecular Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, cc-by-nc-nd)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- Funders
- Associazione Italiana per la Ricerca sul Cancro (15464, 15279, IG-15279)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- Nrf2, Nrf2 signaling, oncogenic function, tumor suppressor, oxidative stress, chemoresistance, radioresistance (biology), Nrf2 inhibitors, therapeutic target, cancer
- MeSH terms
- Kelch-Like ECH-Associated Protein 1, Animals, Antineoplastic Agents, Humans, Mutation, Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Oxidative Stress, MicroRNAs, Epigenesis, Genetic, NF-E2-Related Factor 2, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
